Abstract
This latest Multi Client Publication from HBS Consulting provides:
- An overview of current industry-landscape for molecular diagnostics within the oncology area
- Analysis of the key European markets including forecasts for growth, drivers and restraints in the marketplace
- Reimbursement and legislation environment, the most relevant national guidelines relating to genetic testing
- Understanding of market opportunities for molecular diagnostics within the oncology market as an area of growth, research and future developments
Overview
Project Objectives
The primary objective of this report, compiled from an analysis of primary and secondary research data, is to provide an overview of the molecular diagnostics market for selected oncology markers in the country markets listed below.
- France
- Germany
- Italy
- United Kingdom
- USA
The following key issues have been addressed:
- Provide a reflective picture of the type and number of relevant testing institutions
- Which and how many parameters are tested (market size). Top 3 solid markers, top 3 lymphoid markers and emerging markers identified.
- Which assays are used (home brew or commercial)
- Current market growth per parameter
- Expected market growth rates per parameter in the next 5 years
- Which technologies are used (PCR, RT-PCR, FISH, sequencing, microarrays, others) and what is the anticipated shift in use of these.
- Devices used
- The regulatory issues per country (legislation, reimbursement etc.)
- Future trends & emerging technologies
Table of Contents
Introduction
Part 1 - France
- Current Situation
- Respondent Population France
- Nucleic Acid Based Testing
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumour Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Markers
- CE approval
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 2 - Germany
- Current Situation
- Respondent Population Germany
- Nucleic Acid Based Testing
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in Genetics Based Oncology Diagnostics
- Emerging Markers
- CE certification
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 3 - Italy
- Current Situation
- Respondent Population - Italy
- Nucleic Acid Based Testing
- Types of testing performed
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Markers
- CE or FDA approval
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 4 - United Kingdom
- Current Situation
- Respondent Population UK
- Nucleic Acid Based Testing
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Markers
- CE certification
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 5 - USA
- Current Situation
- Respondent Population US
- Nucleic Acid Based Testing
- Types of testing performed
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Marker
- Test Certification
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
